Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 3Venous Thrombosis 1Venous Thromboembolism 1Thromboembolism 1Pulmonary Embolism 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Lung Neoplasms 1Liver Neoplasms 1Liver Diseases 1Gastrointestinal Neoplasms 1Esophageal Neoplasms 1Digestive System Neoplasms 1Digestive System Diseases 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Adenocarcinoma 1

Interventions

Gemcitabine 74Capecitabine 60Paclitaxel 59Fluorouracil 58Oxaliplatin 57Bevacizumab 51Docetaxel 50Leucovorin 48Nivolumab 40Cisplatin 40Irinotecan 39Carboplatin 37Cetuximab 34pembrolizumab 32Radiosurgery 32Trastuzumab 30Radiotherapy 27Everolimus 24Sorafenib 23Pemetrexed 20Doxorubicin 20Albumin-Bound Paclitaxel 20Ipilimumab 19Cyclophosphamide 19Panitumumab 18Zoledronic Acid 17Lapatinib 17Erlotinib Hydrochloride 17Prednisone 16pazopanib 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Neoplasm Metastasis × Nadroparin × Clear all
NCT00951574 2012-02-01

Prevention of Venous and Arterial Thromboembolism, in Cancer Patients Undergoing Chemotherapy, With a Low Molecular Weight Heparin (Nadroparin Calcium)

Italfarmaco

Phase 3 Completed
1,166 enrolled

Neoplasm Metastasis, Neoplasms, Thromboembolism

Data powered by HemOnc (CC BY 4.0) Colophon âš¡